Milestone Pharmaceuticals Inc.

For the period ended Mar 31, 2026. Filed May 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

MIST$0.74-3.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

Condensed Consolidated Balance Sheets** (Unaudited)**

(in thousands of US dollars, except share data)



· · March 31, 2026 · · December 31, 2025
Assets · · · · ·

Current assets · · · · ·
Cash and cash equivalents	$71,317	$73,046
Short-term investments	112,899	32,914
Accounts receivable, net	1,605	—
License receivable	1,546	1,546
Research and development tax credits receivable	425	316
Prepaid expenses	1,210	1,805
Inventory, net	1,826	648
Other receivables	1,425	1,646
Total current assets	192,253	111,921
Operating lease right-of-use assets	981	1,129
Property and equipment, net	500	511
Total assets	$193,734	$113,561

Liabilities, and Shareholders' Equity

Current liabilities
Accounts payable	$10,023	$5,645
Accrued liabilities	9,803	7,644
Operating lease liabilities	659	647
Deferred revenue	416	—
Other current liabilities	43	43
Total current liabilities	20,944	13,979
Operating lease liabilities, net of current portion	366	539
Senior secured convertible notes	58,192	57,191
Royalty financing obligation, long-term	78,111	—
Other long-term liabilities	72	83
Total liabilities	157,685	71,792


Shareholders’ Equity
Common shares, no par value, unlimited shares authorized, 117,794,417 shares issued and outstanding as of March 31, 2026, 106,236,344 shares issued and outstanding as of December 31, 2025	373,702	352,619
Pre-funded warrants - 16,412,925 issued and outstanding as of March 31, 2026, and 16,412,925 as of December 31, 2025	55,649	55,649
Additional paid-in capital	63,367	64,104
Accumulated deficit	(456,669)	(430,603)

Total shareholders’ equity	36,049	41,769

Total liabilities and shareholders’ equity	$193,734	$113,561

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.